A Case Report on the Development of Ulcerative Colitis During Osimertinib Therapy for Epidermal Growth Factor Receptor Mutation‐Positive Non‐Small‐Cell Lung Cancer
ABSTRACT Osimertinib, a standard treatment for epidermal growth factor receptor (EGFR)‐positive non‐small‐cell lung cancer, commonly causes manageable diarrhoea. We report osimertinib‐induced refractory diarrhoea diagnosed as ulcerative colitis, remitting with mesalazine. A 69‐year‐old woman with ad...
Saved in:
Main Authors: | Tomoki Tamura, Misaki Tani, Hiromichi Ogata, Tomoya Osedo, Masahiro Yamashita, Taisaku Koyanagi, Tatsuya Nishi, Takahiro Umeno, Shoichi Kuyama |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2025-07-01
|
Series: | Respirology Case Reports |
Subjects: | |
Online Access: | https://doi.org/10.1002/rcr2.70272 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Longitudinal Circulating Tumor DNA–Guided Resistance Analysis During Second-Line Osimertinib Treatment
by: J.W. Tijmen van der Wel, MD, et al.
Published: (2025-09-01) -
Fexofenadine Overcomes Osimertinib Resistance by Inhibiting c‐Met in Non‐Small Cell Lung Cancer
by: Kenneth K. W. To, et al.
Published: (2025-06-01) -
Epidermal Nevi and Epidermal Naevus Syndromes
by: Gianluca Tadini, et al.
Published: (2025-08-01) -
BRAF Fusion as Resistance Mechanism to Osimertinib in EGFR-Mutated NSCLC: A Case Report and Review of Literature
by: Marianna Peroni, MD, et al.
Published: (2025-08-01) -
First‐Line Osimertinib for EGFR‐Mutated Squamous Cell Lung Carcinoma: A Case Report
by: Yugo Matsumura, et al.
Published: (2025-07-01)